Ascribe Bio
PrivateLast Round
Series A
Oct 14, 2025
Total Funding Raised
$12.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ascribe Bio operates in Healthcare & Life Sciences and is based in Ithaca, New York. Its latest recorded funding round was a Series A round in October 2025.
Ascribe Bio is an agricultural technology company that develops natural crop protection solutions derived from small molecules found in the soil microbiome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Sustainable Materials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ascribe Bio Comparables
Compare Ascribe Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innatrix, Inc. | 81% | |
| Micropep | 81% | |
| Terramera | 78% |
For institutional investors. Book with your work email.
Ascribe Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 14, 2025 | ||||
| Corporate Funding | Jan 29, 2025 | ||||
| Grant | Nov 17, 2021 |
For institutional investors. Book with your work email.
Ascribe Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Center for Regional Economic Advancement | Grant |
| Cultivation Capital | Series A |
| ICIG Ventures | Corporate Funding |
| Ponderosa Ventures | Grant |
| Acre Venture Partners | Series A, Grant |
| Syngenta Group Ventures | Series A |
| Trailhead Capital | Series A, Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 94% MoM.
- Oct 14, 2025
$12M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 29, 2026
Ascribe Bio launched Phytalix in Brazil on Sep 29th '26.
For institutional investors. Book with your work email.
Ascribe Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ascribe Bio's valuation, stock price, and market status.
Is Ascribe Bio a public or private company?
Ascribe Bio is a private company.
What is the current stock price of Ascribe Bio?
Ascribe Bio is a private company, so its shares have no public market price. Caplight tracks Ascribe Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ascribe Bio worth (valuation)?
Valuation information for Ascribe Bio is not publicly available.
Can I buy Ascribe Bio stock?
Ascribe Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ascribe Bio's last funding round?
Ascribe Bio's most recent funding round was Series A on October 14, 2025.
Who are the main investors in Ascribe Bio?
Key investors in Ascribe Bio include Acre Venture Partners, The Yield Lab.
Will Ascribe Bio IPO soon?
No public IPO plans have been announced for Ascribe Bio.
How can I track Ascribe Bio secondary market activity?
Caplight tracks bids, offers, and trades in Ascribe Bio's shares on secondary markets.